MX2011010359A - Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida. - Google Patents

Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.

Info

Publication number
MX2011010359A
MX2011010359A MX2011010359A MX2011010359A MX2011010359A MX 2011010359 A MX2011010359 A MX 2011010359A MX 2011010359 A MX2011010359 A MX 2011010359A MX 2011010359 A MX2011010359 A MX 2011010359A MX 2011010359 A MX2011010359 A MX 2011010359A
Authority
MX
Mexico
Prior art keywords
benzamide
piperidin
trifluoro
pyridin
methyl
Prior art date
Application number
MX2011010359A
Other languages
English (en)
Spanish (es)
Inventor
Alison Pilgrim
James F White
Nadia M J Rupniak
Original Assignee
Colucid Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42826711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011010359(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colucid Pharmaceuticals Inc filed Critical Colucid Pharmaceuticals Inc
Publication of MX2011010359A publication Critical patent/MX2011010359A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2011010359A 2009-04-02 2010-04-02 Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida. MX2011010359A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16609709P 2009-04-02 2009-04-02
PCT/US2010/029810 WO2010115125A2 (en) 2009-04-02 2010-04-02 Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide

Publications (1)

Publication Number Publication Date
MX2011010359A true MX2011010359A (es) 2012-02-23

Family

ID=42826711

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010359A MX2011010359A (es) 2009-04-02 2010-04-02 Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.

Country Status (26)

Country Link
US (3) US20100256187A1 (https=)
EP (1) EP2413933B2 (https=)
JP (9) JP5727457B2 (https=)
KR (1) KR101697801B1 (https=)
CN (2) CN107412230A (https=)
AU (1) AU2010232497B2 (https=)
CA (1) CA2757019C (https=)
CY (2) CY1119785T1 (https=)
DK (1) DK2413933T4 (https=)
ES (1) ES2655881T5 (https=)
FI (1) FIC20230001I1 (https=)
FR (1) FR23C1002I2 (https=)
HK (1) HK1243923A1 (https=)
HR (1) HRP20171742T4 (https=)
HU (2) HUE037261T2 (https=)
IL (1) IL215483A (https=)
LT (2) LT2413933T (https=)
LU (1) LUC00295I2 (https=)
MX (1) MX2011010359A (https=)
NL (1) NL301214I2 (https=)
NO (2) NO2413933T3 (https=)
NZ (1) NZ596161A (https=)
PL (1) PL2413933T5 (https=)
PT (1) PT2413933T (https=)
SI (1) SI2413933T2 (https=)
WO (1) WO2010115125A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
WO2009145842A2 (en) 2008-04-04 2009-12-03 Forsight Labs, Llc Therapeutic device for pain management and vision
PL2413933T5 (pl) 2009-04-02 2021-10-18 Colucid Pharmaceuticals, Inc. 2,4,6-trifluoro-N-[6-(1-metylopiperydyno-4-karbonylo)pirydyn-2-ylo]benzamid do leczenia migreny drogą doustną lub dożylną
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
US12044905B2 (en) 2011-04-28 2024-07-23 Journey1 Inc Contact lenses for refractive correction
CA2916885A1 (en) 2013-06-26 2014-12-31 Nexisvision, Inc. Contact lenses for refractive correction
KR20190075130A (ko) 2016-12-06 2019-06-28 코루시드 파마슈티컬즈 인코포레이티드 피리디노일피페리딘 5-ht1f 작용제에 관한 조성물 및 방법
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
TWI776175B (zh) 2019-07-09 2022-09-01 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JPH03255426A (ja) 1990-03-06 1991-11-14 Toshiba Corp 有機非線形光学材料
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5360735A (en) 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
NZ305166A (en) * 1995-03-20 1998-12-23 Lilly Co Eli 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
US5942536A (en) 1995-10-10 1999-08-24 Eli Lilly And Company N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
BR9711273A (pt) 1996-08-28 1999-08-17 Lilly Co Eli 1,2,3,4- Tetraidro-2-dibenzofuranaminas substituidas e 2- aminociclohepta b benzofuranos
AU4652697A (en) 1996-10-08 1998-05-05 Eli Lilly And Company New serotonin 5-ht1f agonists
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP0875513A1 (en) 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
ID23053A (id) 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
US5905084A (en) 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
AU4961499A (en) 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
JP2002519348A (ja) 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー ５−ｈｔ１ｆアゴニスト
US6608079B1 (en) 1998-12-11 2003-08-19 Eli Lilly And Company Indole derivatives and their use as 5-HT1F agonists
DE60036924T2 (de) 1999-02-10 2008-08-14 Eli Lilly And Co., Indianapolis 5-ht1f agonisten
US6777428B1 (en) * 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
AU3354000A (en) 1999-02-26 2000-09-14 Eli Lilly And Company 5-ht1f agonists
WO2002006196A1 (en) 2000-07-13 2002-01-24 Merck Patent Gmbh Chiral compounds i
US6650463B2 (en) * 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
WO2003000245A1 (en) 2001-06-22 2003-01-03 Poseidon Pharmaceuticals A/S Compounds for use in disorders associated with mast cell or basophil activity
TWI263497B (en) * 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
AU2003295782A1 (en) * 2002-11-22 2004-06-18 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
MXPA05011223A (es) * 2003-04-18 2006-01-26 Lilly Co Eli Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif.
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
US7915293B2 (en) * 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
UA82711C2 (en) * 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
AU2005311251A1 (en) 2004-12-01 2006-06-08 Devgen Nv 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the Kv family
KR20060067738A (ko) * 2004-12-15 2006-06-20 주식회사 대웅제약 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 신규한 ｎ-아릴아마이드 유도체 및 이를함유하는 약제학적 조성물
US20060178349A1 (en) * 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
KR100976063B1 (ko) * 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
PL2413933T5 (pl) † 2009-04-02 2021-10-18 Colucid Pharmaceuticals, Inc. 2,4,6-trifluoro-N-[6-(1-metylopiperydyno-4-karbonylo)pirydyn-2-ylo]benzamid do leczenia migreny drogą doustną lub dożylną
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
KR20190075130A (ko) 2016-12-06 2019-06-28 코루시드 파마슈티컬즈 인코포레이티드 피리디노일피페리딘 5-ht1f 작용제에 관한 조성물 및 방법
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
TWI776175B (zh) 2019-07-09 2022-09-01 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備

Also Published As

Publication number Publication date
US12257246B2 (en) 2025-03-25
FR23C1002I2 (fr) 2023-11-24
EP2413933B1 (en) 2017-11-01
JP2023175694A (ja) 2023-12-12
JP6887462B2 (ja) 2021-06-16
HRP20171742T1 (hr) 2018-02-09
JP2018087247A (ja) 2018-06-07
EP2413933A4 (en) 2012-09-19
HUS2300004I1 (hu) 2023-02-28
SI2413933T1 (en) 2018-04-30
JP7566996B2 (ja) 2024-10-15
LUC00295I2 (https=) 2025-09-22
CY1119785T1 (el) 2018-06-27
FIC20230001I1 (fi) 2023-01-10
US20250228839A1 (en) 2025-07-17
JP7335397B2 (ja) 2023-08-29
PL2413933T3 (pl) 2018-04-30
JP2012522805A (ja) 2012-09-27
DK2413933T3 (da) 2018-01-29
EP2413933A2 (en) 2012-02-08
US20210401822A1 (en) 2021-12-30
AU2010232497A1 (en) 2011-11-24
DK2413933T4 (da) 2021-08-23
CY2023001I1 (el) 2023-03-24
KR20110136893A (ko) 2011-12-21
NO2023002I1 (no) 2023-01-05
EP2413933B2 (en) 2021-06-09
WO2010115125A3 (en) 2011-02-17
JP2022163049A (ja) 2022-10-25
JP2021152008A (ja) 2021-09-30
US20100256187A1 (en) 2010-10-07
CN107412230A (zh) 2017-12-01
PT2413933T (pt) 2017-12-12
IL215483A (en) 2017-07-31
WO2010115125A2 (en) 2010-10-07
LTC2413933I2 (https=) 2025-03-10
JP2016188241A (ja) 2016-11-04
JP7110446B2 (ja) 2022-08-01
ES2655881T3 (es) 2018-02-22
JP2025020117A (ja) 2025-02-12
LT2413933T (lt) 2018-02-26
CA2757019C (en) 2018-05-15
JP2015013903A (ja) 2015-01-22
JP5727457B2 (ja) 2015-06-03
HUE037261T2 (hu) 2018-08-28
KR101697801B1 (ko) 2017-01-18
PL2413933T5 (pl) 2021-10-18
CA2757019A1 (en) 2010-10-07
NL301214I1 (https=) 2023-01-25
NL301214I2 (nl) 2023-04-19
LTPA2023502I1 (https=) 2023-01-25
AU2010232497B2 (en) 2016-05-19
IL215483A0 (en) 2011-12-29
FR23C1002I1 (fr) 2023-03-10
HK1243923A1 (zh) 2018-07-27
CY2023001I2 (el) 2023-06-09
HRP20171742T4 (hr) 2021-08-06
CN102753171A (zh) 2012-10-24
ES2655881T5 (es) 2021-11-25
SI2413933T2 (sl) 2021-09-30
NO2413933T3 (https=) 2018-03-31
JP2019189617A (ja) 2019-10-31
NZ596161A (en) 2013-11-29

Similar Documents

Publication Publication Date Title
MX2011010359A (es) Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
ZA200807274B (en) Novel pyridine derivatives
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
TN2012000195A1 (en) Solid dispersion of rifaximin
TN2011000466A1 (en) Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
TW200942530A (en) Pyridine compounds
TW201711676A (en) Ferric citrate dosage forms
MY154909A (en) Novel thiophene derivatives
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
TN2012000549A1 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
MX2011007930A (es) Conjugados de insulina cristalina.
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
TW200942524A (en) Novel aminomethyl benzene derivatives
SG171542A1 (en) Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin
EP2575464A4 (en) NEW FORMS OF RIFAXIMINE AND APPLICATIONS THEREOF
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
TN2012000105A1 (en) Spirolactam derivatives and uses of same
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
MX2010002506A (es) Compuestos de nicotinamida sustituidos y uso de estos en medicamentos.
MX2013012918A (es) Formulaciones de liberacion sostenida de paracetamol.

Legal Events

Date Code Title Description
FG Grant or registration